302 related articles for article (PubMed ID: 31200515)
21. Telomerase promoter mutations in cancer: an emerging molecular biomarker?
Vinagre J; Pinto V; Celestino R; Reis M; Pópulo H; Boaventura P; Melo M; Catarino T; Lima J; Lopes JM; Máximo V; Sobrinho-Simões M; Soares P
Virchows Arch; 2014 Aug; 465(2):119-33. PubMed ID: 25048572
[TBL] [Abstract][Full Text] [Related]
22. TERT promoter mutations and telomeres during tumorigenesis.
Lorbeer FK; Hockemeyer D
Curr Opin Genet Dev; 2020 Feb; 60():56-62. PubMed ID: 32163830
[TBL] [Abstract][Full Text] [Related]
23. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
24. DNA methylation of the TERT promoter and its impact on human cancer.
Lee DD; Komosa M; Nunes NM; Tabori U
Curr Opin Genet Dev; 2020 Feb; 60():17-24. PubMed ID: 32114294
[TBL] [Abstract][Full Text] [Related]
25. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
26. TERT Promoter Mutations in Papillary Thyroid Microcarcinomas.
de Biase D; Gandolfi G; Ragazzi M; Eszlinger M; Sancisi V; Gugnoni M; Visani M; Pession A; Casadei G; Durante C; Costante G; Bruno R; Torlontano M; Paschke R; Filetti S; Piana S; Frasoldati A; Tallini G; Ciarrocchi A
Thyroid; 2015 Sep; 25(9):1013-9. PubMed ID: 26148423
[TBL] [Abstract][Full Text] [Related]
27. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
[TBL] [Abstract][Full Text] [Related]
28. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
[TBL] [Abstract][Full Text] [Related]
29. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
[TBL] [Abstract][Full Text] [Related]
30. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant
Fotouhi O; Ghaderi M; Wang N; Zedenius J; Kjellman M; Xu D; Juhlin CC; Larsson C
Epigenetics; 2019 Dec; 14(12):1224-1233. PubMed ID: 31322481
[TBL] [Abstract][Full Text] [Related]
31. Identification of Recurrent TERT Promoter Mutations in Intrathyroid Thymic Carcinomas.
Tahara I; Oishi N; Mochizuki K; Oyama T; Miyata K; Miyauchi A; Hirokawa M; Katoh R; Kondo T
Endocr Pathol; 2020 Sep; 31(3):274-282. PubMed ID: 32594366
[TBL] [Abstract][Full Text] [Related]
32. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS
Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876
[TBL] [Abstract][Full Text] [Related]
33. Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer.
Kim TH; Ki CS; Hahn SY; Oh YL; Jang HW; Kim SW; Chung JH; Shin JH
Endocrine; 2017 Aug; 57(2):234-240. PubMed ID: 28616852
[TBL] [Abstract][Full Text] [Related]
34. Re: TERT Promoter Mutations and Telomerase Reactivation in Urothelial Cancer.
Atala A
J Urol; 2015 Sep; 194(3):848. PubMed ID: 26292896
[No Abstract] [Full Text] [Related]
35. Effects of Coexistent BRAF
Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
[TBL] [Abstract][Full Text] [Related]
36. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
[TBL] [Abstract][Full Text] [Related]
37. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
38. Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.
Rachakonda S; Kong H; Srinivas N; Garcia-Casado Z; Requena C; Fallah M; Heidenreich B; Planelles D; Traves V; Schadendorf D; Nagore E; Kumar R
Genes Chromosomes Cancer; 2018 Nov; 57(11):564-572. PubMed ID: 30203894
[TBL] [Abstract][Full Text] [Related]
39. Understanding TERT Promoter Mutations: A Common Path to Immortality.
Bell RJ; Rube HT; Xavier-Magalhães A; Costa BM; Mancini A; Song JS; Costello JF
Mol Cancer Res; 2016 Apr; 14(4):315-23. PubMed ID: 26941407
[TBL] [Abstract][Full Text] [Related]
40. TERT promoter mutations and long-term survival in patients with thyroid cancer.
Kim TH; Kim YE; Ahn S; Kim JY; Ki CS; Oh YL; Kim K; Yun JW; Park WY; Choe JH; Kim JH; Kim JS; Kim SW; Chung JH
Endocr Relat Cancer; 2016 Oct; 23(10):813-23. PubMed ID: 27528624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
